Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1169723

Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources.

Pasic, Anes; Simetic, Luka; Herceg, Davorin; Ceric, Timur; Kapisazovic, Elma; Beslija, Semir
Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources. // 2018 ASCO Annual Meeting I. U: Journal of Clinical Oncology: an American Society of Clinical Oncology Journal 2018 ; 36(Suppl. 15)
online, 2018. str. e23555-e23555 doi:10.1200/jco.2018.36.15_suppl.e23555 (poster, međunarodna recenzija, sažetak, stručni)

CROSBI ID: 1169723 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources.

Autori
Pasic, Anes ; Simetic, Luka ; Herceg, Davorin ; Ceric, Timur ; Kapisazovic, Elma ; Beslija, Semir

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
2018 ASCO Annual Meeting I. U: Journal of Clinical Oncology: an American Society of Clinical Oncology Journal 2018 ; 36(Suppl. 15) / - , 2018, E23555-e23555

Skup
2018 ASCO Annual Meeting I

Mjesto i datum
Online, 01.06.2018. - 05.06.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
soft tissue sarcoma ; systemic treatment ; pazopanib ; trabectedin

Sažetak
Soft tissue sarcomas (STS) are rare tumors with more than 50 histologic subtypes. Treatment outcomes for patients with STS has improved over the past few decades mostly due to the adoption of a multidisciplinary approach, but still patients with advanced disease have a poor prognosis.Our study compared efficacy of novel sarcoma therapies - pazopanib and trabectedin vs standard chemotherapy, after failure to anthracycline based therapy, in patients with metastatic STS

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
Stomatološki fakultet, Zagreb,
Klinički bolnički centar Zagreb

Profili:

Avatar Url Davorin Herceg (autor)

Avatar Url Luka Simetić (autor)

Poveznice na cjeloviti tekst rada:

doi ascopubs.org

Citiraj ovu publikaciju:

Pasic, Anes; Simetic, Luka; Herceg, Davorin; Ceric, Timur; Kapisazovic, Elma; Beslija, Semir
Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources. // 2018 ASCO Annual Meeting I. U: Journal of Clinical Oncology: an American Society of Clinical Oncology Journal 2018 ; 36(Suppl. 15)
online, 2018. str. e23555-e23555 doi:10.1200/jco.2018.36.15_suppl.e23555 (poster, međunarodna recenzija, sažetak, stručni)
Pasic, A., Simetic, L., Herceg, D., Ceric, T., Kapisazovic, E. & Beslija, S. (2018) Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources.. U: 2018 ASCO Annual Meeting I. U: Journal of Clinical Oncology: an American Society of Clinical Oncology Journal 2018 ; 36(Suppl. 15) doi:10.1200/jco.2018.36.15_suppl.e23555.
@article{article, author = {Pasic, Anes and Simetic, Luka and Herceg, Davorin and Ceric, Timur and Kapisazovic, Elma and Beslija, Semir}, year = {2018}, pages = {e23555-e23555}, DOI = {10.1200/jco.2018.36.15\_suppl.e23555}, keywords = {soft tissue sarcoma, systemic treatment, pazopanib, trabectedin}, doi = {10.1200/jco.2018.36.15\_suppl.e23555}, title = {Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources.}, keyword = {soft tissue sarcoma, systemic treatment, pazopanib, trabectedin}, publisherplace = {online} }
@article{article, author = {Pasic, Anes and Simetic, Luka and Herceg, Davorin and Ceric, Timur and Kapisazovic, Elma and Beslija, Semir}, year = {2018}, pages = {e23555-e23555}, DOI = {10.1200/jco.2018.36.15\_suppl.e23555}, keywords = {soft tissue sarcoma, systemic treatment, pazopanib, trabectedin}, doi = {10.1200/jco.2018.36.15\_suppl.e23555}, title = {Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources.}, keyword = {soft tissue sarcoma, systemic treatment, pazopanib, trabectedin}, publisherplace = {online} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.